Kyaw thura zaw
•Download as PPT, PDF•
1 like•622 views
1) The document compares poly-chemotherapy (CVD regimen) and the same chemotherapy (CT) plus interferon-α2a in treating metastatic melanoma. 2) It studies 15 patients receiving either CVD alone or CVD plus interferon-α2a and finds the response rate was highest in the combined treatment group, though not significantly. 3) The median survival was 12 months for both groups, with the combined treatment group having a slightly higher average survival time.
Report
Share
Report
Share
![INTRODUCTION ,[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Multidisciplinary approach to the management of leukemias aml
The document discusses the multidisciplinary approach to managing leukemias like AML and MDS. It presents the case of a 68-year old male patient presenting with fever and fatigue, and details the diagnostic workup showing features consistent with acute myeloid leukemia. The document then reviews classification, prognostic factors, recent treatment trials, and the role of allogeneic stem cell transplantation for AML patients.
Chapter 26 chemoprevention of cancer
Chemoprevention seeks to use natural, synthetic, or biological agents to prevent cancer development and progression. It can involve blocking cancer initiation through agents that prevent DNA damage from carcinogens. It can also suppress promotion and progression of initiated cells through inhibition of signal transduction pathways. The FDA has approved selective estrogen receptor modulators like tamoxifen and raloxifene for breast cancer chemoprevention and aspirin use has been associated with reduced colorectal cancer risk. However, some agents like beta-carotene and retinoids have been found to increase cancer risk in smokers.
Biomarkers in cancer
Biomarkers have a diversified role in diagnosis, prognostication and risk stratification. This presentation aims to compile the basic information and new literature on various biomarkers pertaining to cancer care.
Chemotherapy 101
This document provides an overview of chemotherapy principles and common agents for internal medicine house staff. It begins with frameworks for understanding antineoplastic agents and reviews basic chemotherapy principles. It then discusses the different modalities of cancer treatment including surgery, radiation, chemotherapy, targeted therapies, immunotherapy and hormonal therapy. Specific sections cover common chemotherapy agents, their mechanisms of action, uses and side effects.
Timeliness in diagnosis of acute leukemia in paediatric age group
The document discusses acute leukemia in pediatric patients. It notes that leukemia and lymphoma are the most common cancers in children globally. It describes some of the typical presentations of acute leukemia in children, which can include symptoms like fatigue, fever, bruising, and organ enlargement due to infiltration of leukemia cells. The document outlines some potential life-threatening complications and discusses tests that are used in the diagnosis of childhood leukemia, including blood tests, bone marrow aspiration and biopsy, lumbar puncture, and cytogenetic testing.
Chemotherapy and Prostate Cancer
Prostate cancer is one of the most common cancers in men over 50 and is highly treatable if diagnosed early, with active surveillance often sufficient to control early-stage disease. For more advanced prostate cancer, chemotherapy may help by using drugs that travel through the bloodstream to fight cancer in other organs. Doctors may prescribe chemotherapy like docetaxel and prednisone if prostate cancer spreads outside the prostate gland and stops responding to hormone therapy, replacing docetaxel if the initial treatment fails.
Cancer gastrico adyuvancia
The document discusses adjuvant treatment options for gastric cancer based on several clinical trials. It finds that adjuvant chemotherapy provides a 5.8% absolute benefit in 5-year overall survival compared to surgery alone. Adjuvant chemoradiotherapy may provide additional benefits for patients with D1 resections, lymph node ratios over 25%, or intestinal-type gastric cancers. Specifically, one trial found 5-year disease-free survival was 55% with chemoradiotherapy versus 28% with chemotherapy alone for these high-risk patients. The document concludes that adjuvant chemoradiotherapy should be considered for these poor prognosis patients when neoadjuvant treatment is not possible due to poor performance status.
Highlights from asco gu 2017
This document summarizes a presentation on prostate cancer research from the 2017 ASCO GU conference. It covered several topics:
1. Disease demographics, including that 50% of patients present with metastatic disease and mortality rates are changing.
2. Pathology classification of prostate cancer.
3. Treatment options for localized disease including surgery, radiation, and their outcomes.
4. Clinical trials on treatments for metastatic disease such as the Stampede and TERRAIN trials.
5. Research on DNA repair genes and intrinsic subtypes of prostate cancer predicting treatment responses.
Recommended
Multidisciplinary approach to the management of leukemias aml
The document discusses the multidisciplinary approach to managing leukemias like AML and MDS. It presents the case of a 68-year old male patient presenting with fever and fatigue, and details the diagnostic workup showing features consistent with acute myeloid leukemia. The document then reviews classification, prognostic factors, recent treatment trials, and the role of allogeneic stem cell transplantation for AML patients.
Chapter 26 chemoprevention of cancer
Chemoprevention seeks to use natural, synthetic, or biological agents to prevent cancer development and progression. It can involve blocking cancer initiation through agents that prevent DNA damage from carcinogens. It can also suppress promotion and progression of initiated cells through inhibition of signal transduction pathways. The FDA has approved selective estrogen receptor modulators like tamoxifen and raloxifene for breast cancer chemoprevention and aspirin use has been associated with reduced colorectal cancer risk. However, some agents like beta-carotene and retinoids have been found to increase cancer risk in smokers.
Biomarkers in cancer
Biomarkers have a diversified role in diagnosis, prognostication and risk stratification. This presentation aims to compile the basic information and new literature on various biomarkers pertaining to cancer care.
Chemotherapy 101
This document provides an overview of chemotherapy principles and common agents for internal medicine house staff. It begins with frameworks for understanding antineoplastic agents and reviews basic chemotherapy principles. It then discusses the different modalities of cancer treatment including surgery, radiation, chemotherapy, targeted therapies, immunotherapy and hormonal therapy. Specific sections cover common chemotherapy agents, their mechanisms of action, uses and side effects.
Timeliness in diagnosis of acute leukemia in paediatric age group
The document discusses acute leukemia in pediatric patients. It notes that leukemia and lymphoma are the most common cancers in children globally. It describes some of the typical presentations of acute leukemia in children, which can include symptoms like fatigue, fever, bruising, and organ enlargement due to infiltration of leukemia cells. The document outlines some potential life-threatening complications and discusses tests that are used in the diagnosis of childhood leukemia, including blood tests, bone marrow aspiration and biopsy, lumbar puncture, and cytogenetic testing.
Chemotherapy and Prostate Cancer
Prostate cancer is one of the most common cancers in men over 50 and is highly treatable if diagnosed early, with active surveillance often sufficient to control early-stage disease. For more advanced prostate cancer, chemotherapy may help by using drugs that travel through the bloodstream to fight cancer in other organs. Doctors may prescribe chemotherapy like docetaxel and prednisone if prostate cancer spreads outside the prostate gland and stops responding to hormone therapy, replacing docetaxel if the initial treatment fails.
Cancer gastrico adyuvancia
The document discusses adjuvant treatment options for gastric cancer based on several clinical trials. It finds that adjuvant chemotherapy provides a 5.8% absolute benefit in 5-year overall survival compared to surgery alone. Adjuvant chemoradiotherapy may provide additional benefits for patients with D1 resections, lymph node ratios over 25%, or intestinal-type gastric cancers. Specifically, one trial found 5-year disease-free survival was 55% with chemoradiotherapy versus 28% with chemotherapy alone for these high-risk patients. The document concludes that adjuvant chemoradiotherapy should be considered for these poor prognosis patients when neoadjuvant treatment is not possible due to poor performance status.
Highlights from asco gu 2017
This document summarizes a presentation on prostate cancer research from the 2017 ASCO GU conference. It covered several topics:
1. Disease demographics, including that 50% of patients present with metastatic disease and mortality rates are changing.
2. Pathology classification of prostate cancer.
3. Treatment options for localized disease including surgery, radiation, and their outcomes.
4. Clinical trials on treatments for metastatic disease such as the Stampede and TERRAIN trials.
5. Research on DNA repair genes and intrinsic subtypes of prostate cancer predicting treatment responses.
CRPC
This document discusses treatment options for castration-resistant prostate cancer (CRPC). It describes how CRPC is defined and various treatment approaches. Key points:
- CRPC is defined as disease progression despite castrate levels of testosterone (<50 ng/dL) through rising PSA levels, new bone lesions, or soft tissue metastases.
- Common treatments include secondary hormonal therapies like abiraterone or enzalutamide, cytotoxic chemotherapies like docetaxel or cabazitaxel, immunotherapy like sipuleucel-T, and novel targeted agents.
- Choice of treatment depends on factors like metastasis status, symptoms, performance status, and prior docetax
Multiple myeloma and plasmacytoma
This document provides an overview of the management of plasma cell neoplasms including multiple myeloma and plasmacytoma. It discusses the clinical spectrum, epidemiology, etiology, pathogenesis, clinical features, evaluation, staging systems, imaging, and management approaches including treatment regimens for newly diagnosed, relapsed, and transplant eligible or ineligible patients. It also reviews treatment of complications such as bone disease, anemia, renal failure, and infections. Management involves risk-stratified chemotherapy, stem cell transplantation, radiation, surgery, bisphosphonates, and palliative care.
Cancer biomarker
What is biomarker?
What is the purpose of biomarker
Processes of biomarker development?
Types of Biomarkers
What is biomarker testing for cancer treatment?
Uses of Biomarkers in Cancer Medicine
Uses of Biomarkers in Cancer Drug Discovery
Current and emerging biomarkers of breast cancer
The document summarizes current and emerging biomarkers for breast cancer. It discusses established biomarkers like p53, HER2, BRCA1, and BRCA2, which are involved in processes like DNA damage response and repair. Emerging biomarkers discussed include Ki-67, which is involved in cell proliferation, and Cyclin D1, which regulates cell cycle. The document also reviews how certain foods and dietary components can influence these biomarkers and potentially reduce breast cancer risk by promoting apoptosis, DNA repair, and reducing inflammation. Maintaining a healthy diet and lifestyle is recommended for breast cancer prevention and treatment.
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...Health Sciences North | Horizon Santé Nord
This document discusses how genomics is changing cancer care. It explains that while most cancers are sporadic, genomic testing can be used to identify hereditary cancer risk factors based on family history, pathology, and personal history. It also outlines how genomic analysis of tumor cells can provide information for prognosis, targeted therapy, and screening. The future of cancer care will likely involve more widespread, cheaper, and faster genomic testing to enable personalized treatment and pharmacogenomic testing.Basic principles of cancer therapy
Chemotherapy uses cytotoxic drugs to treat cancer by killing cancer cells. There are several types of chemotherapy treatments that are selected based on the type, stage, and genetics of the cancer. The goals of chemotherapy can be curative, aiming to eradicate the cancer through induction, consolidation, and maintenance therapy, or palliative to provide comfort and improve quality of life for advanced cancers. A case study is then presented to demonstrate chemotherapy treatment in practice.
Crpc the paradigm of sequence
Describing the importance and how to choose the first line in CRPC emphasising the role of chemotherapy.
NEOPLASIA: CARCINOGENESIS
Carcinogenesis is a multistep process involving genetic mutations that cause cells to proliferate uncontrollably. There are four classes of regulatory genes involved: 1) growth promoters like proto-oncogenes that become activated oncogenes, 2) inhibitors like tumor suppressor genes, 3) genes regulating apoptosis, and 4) DNA repair genes. Genetic damage occurs through environmental and spontaneous mutations and fails to be repaired if the DNA damage response is defective. This can result in oncogene activation and tumor suppressor inactivation, leading to autonomous growth, evasion of growth inhibition, apoptosis resistance, limitless replication through telomerase expression, angiogenesis, invasion and metastasis. Cancer progression involves the accumulation of additional mutations that
Cancer biology
Cancer biochemistry involves biochemical alterations in cancer cells. Specific objectives include listing protooncogenes and tumor suppressor genes, and explaining their roles and mechanisms of action. Protooncogenes become oncogenes through activation mechanisms like mutations. Tumor suppressor genes like p53 regulate cell proliferation and their mutation leads to cancer. Cyclins and cell cycle phases are also discussed. Standard cancer treatments include surgery, radiotherapy, and chemotherapy using antimetabolite drugs. Tumor markers can be used for cancer diagnosis, prognosis, localization, and treatment monitoring and are classified based on their type.
General principles in chemotherapy of cancer
This document provides an overview of general principles in cancer chemotherapy. It discusses that chemotherapy uses cytotoxic drugs to destroy malignant cells. Drugs can be cell cycle specific, killing dividing cells, or nonspecific, killing resting and dividing cells. Combination chemotherapy using multiple drugs with different mechanisms of action is now common to achieve total tumor cell kill. Careful scheduling of cell cycle specific and nonspecific drugs is important. Tumors can become resistant to repeated use of single drugs through selection of less responsive cells or mutations altering drug targets. The goal of chemotherapy is complete remission through use of maximum tolerated drug doses in combination regimens.
IHC in breast CA
1) Breast cancer subtypes are classified based on receptor expression as luminal, basal, or HER2-enriched and these subtypes determine treatment options and prognosis.
2) IHC testing plays an important role in classifying subtypes but results can be affected by testing methods. ER, HER2, and Ki67 are key markers but cut-offs and interpretation require care.
3) The 21-gene Oncotype DX assay provides a recurrence score that predicts chemotherapy benefit in node-negative breast cancer, guiding treatment decisions according to risk categories defined in clinical trials.
Leptomeningeal mets in solid tumors
This document discusses leptomeningeal metastasis (LM), including:
- LM occurs in 5% of cancer patients symptomatically and 20% asymptomatically, most commonly from breast, lung, melanoma, and gastrointestinal cancers.
- Symptoms include headache, vomiting, altered mental status, cranial nerve palsies, and neck stiffness in rare cases.
- MRI of the entire neuraxis is the most sensitive imaging method. CSF analysis has a sensitivity of 45-55% initially, increasing to 80% with a second lumbar puncture.
- Treatment options discussed include surgery, radiation therapy targeted to involved sites, whole brain radiation, and intraventricular chemotherapy via Ommaya reservoir. Median survival is
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Fight Colorectal Cancer
This document summarizes key findings from the PRIME trial evaluating the addition of panitumumab to FOLFOX4 as first-line treatment for metastatic colorectal cancer. Biomarker analysis found that KRAS exon 2 wild-type tumors derived greater benefit from the addition of panitumumab, with a progression-free survival advantage compared to FOLFOX4 alone. Further biomarker testing found mutations in other RAS isoforms or BRAF reduced likelihood of benefit from panitumumab. The results support use of RAS/BRAF mutation testing to select patients for first-line anti-EGFR therapy in combination with chemotherapy.Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...
Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...Prof. Eric Raymond Oncologie Medicale
This oral presentation made during ESMO 2016 highlight novel targets and drugs developed for patients with advanced neuroendocrine tumors. This includes targeted agents aiming probing cell signaling in tumor microenvironment and immune responses. Genetic alterations on major anti-oncogenes are reported in the perspective of pathway activations. Combinations using VEGFR, mTOR, Somatostatin receptors inhibitors with novel strategies and immunotherapy are also suggested. This presentation focuses mainly on gastrointestinal neuroendocrine tumors but may also be of interest for those involved in the care of patients with thoracic neuroendocrine tumors.Chapter 5 hereditary cancer syndrome next generation
This document provides an overview of hereditary cancers and genetic testing. It discusses:
- The difference between sporadic and hereditary cancers, with hereditary cancers making up 10% of cases and being caused by germline mutations passed down from a parent.
- Several hereditary cancer syndromes are described in detail, including BRCA1/2 associated with breast and ovarian cancer, Li-Fraumeni syndrome, Cowden syndrome, and Lynch syndrome.
- Surveillance recommendations are provided for each syndrome to enable early cancer detection.
- The role of genetic testing is discussed to identify mutations that cause hereditary cancer syndromes and guide patient management.
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
This randomized clinical trial compared autologous stem cell transplantation (ASCT) versus continued therapy without transplantation in newly diagnosed multiple myeloma patients. 389 patients received induction with lenalidomide-dexamethasone (Rd) or cyclophosphamide-lenalidomide-dexamethasone (CRD). Patients were then randomized to receive ASCT or continued Rd or CRD therapy. The primary endpoint was progression-free survival (PFS). Results showed ASCT improved PFS compared to continued therapy without transplantation. However, overall survival was not significantly different between the two groups, suggesting continued therapy without ASCT may be sufficient for some patients.
Indolent Non-Hodgkin’s Lymphoma Sharman slides
This document discusses indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It provides information on treatment options and clinical trials for these conditions. The document lists faculty members and their disclosures. It then provides data from clinical trials comparing rituximab maintenance therapy to watchful waiting in asymptomatic follicular lymphoma, and comparing rituximab maintenance to retreatment in low tumor burden follicular lymphoma. Outcomes for different chemotherapy regimens in lymphoma are also presented.
Genomics and Cancer
The study of cancer genomes has revealed abnormalities in genes that drive the development and growth of many types of cancer. This knowledge has improved our understanding of the biology of cancer and led to new methods of diagnosing and treating the disease.
A 2020 Renal Cancer update
An update of the pathophysiology of renal cell cancer including the latest therapeutic pathways and management
Chapter 38 role of surgery in cancer prevention
The document discusses the role of surgery in preventing cancers caused by hereditary genetic mutations. It focuses on several high-risk cancer syndromes including BRCA1/2 mutations which increase breast and ovarian cancer risk, CDH1 mutations which increase stomach cancer risk, and APC mutations which cause Familial Adenomatous Polyposis (FAP) and increase colon cancer risk. For each, it describes the associated cancer risks, genetic testing recommendations, surveillance guidelines, and risk-reducing surgical options such as prophylactic mastectomies, salpingo-oophorectomies, and gastrectomies. The timing of such surgeries is based on the earliest age of cancer onset in the
Aung citt nyein
This study evaluated the efficacy and toxicity of a complex combination biochemotherapy regimen for 25 patients with advanced metastatic melanoma. A complete response was seen in 2 patients, partial response in 2 patients, and stable disease in 9 patients. The most common toxicities were lethargy, fever, nausea, vomiting, thrombocytopenia, leukopenia, and neutropenia. Doses of vindesine, cisplatin, and IL-2 often had to be reduced due to toxicities. The regimen showed an objective response rate of 16% with an 8% complete response rate, but dose reductions were frequently required due to treatment-related side effects.
Sithu ko
The document analyzes the frequency and types of congenital heart diseases in newborns admitted to Tuschinskaya Children's Hospital from 2000 to 2009. It found that septal defects were the most common at 95.6% of cases, with atrial septal defects being the most frequent at 80.5%. The median frequency of congenital heart diseases in newborns each year was 4%. Patients were treated medically to address symptoms until they could undergo surgical treatment. A case study of a newborn with atrioventricular septal defect and patent ductus arteriosus requiring intensive care treatment is also described.
More Related Content
What's hot
CRPC
This document discusses treatment options for castration-resistant prostate cancer (CRPC). It describes how CRPC is defined and various treatment approaches. Key points:
- CRPC is defined as disease progression despite castrate levels of testosterone (<50 ng/dL) through rising PSA levels, new bone lesions, or soft tissue metastases.
- Common treatments include secondary hormonal therapies like abiraterone or enzalutamide, cytotoxic chemotherapies like docetaxel or cabazitaxel, immunotherapy like sipuleucel-T, and novel targeted agents.
- Choice of treatment depends on factors like metastasis status, symptoms, performance status, and prior docetax
Multiple myeloma and plasmacytoma
This document provides an overview of the management of plasma cell neoplasms including multiple myeloma and plasmacytoma. It discusses the clinical spectrum, epidemiology, etiology, pathogenesis, clinical features, evaluation, staging systems, imaging, and management approaches including treatment regimens for newly diagnosed, relapsed, and transplant eligible or ineligible patients. It also reviews treatment of complications such as bone disease, anemia, renal failure, and infections. Management involves risk-stratified chemotherapy, stem cell transplantation, radiation, surgery, bisphosphonates, and palliative care.
Cancer biomarker
What is biomarker?
What is the purpose of biomarker
Processes of biomarker development?
Types of Biomarkers
What is biomarker testing for cancer treatment?
Uses of Biomarkers in Cancer Medicine
Uses of Biomarkers in Cancer Drug Discovery
Current and emerging biomarkers of breast cancer
The document summarizes current and emerging biomarkers for breast cancer. It discusses established biomarkers like p53, HER2, BRCA1, and BRCA2, which are involved in processes like DNA damage response and repair. Emerging biomarkers discussed include Ki-67, which is involved in cell proliferation, and Cyclin D1, which regulates cell cycle. The document also reviews how certain foods and dietary components can influence these biomarkers and potentially reduce breast cancer risk by promoting apoptosis, DNA repair, and reducing inflammation. Maintaining a healthy diet and lifestyle is recommended for breast cancer prevention and treatment.
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...Health Sciences North | Horizon Santé Nord
This document discusses how genomics is changing cancer care. It explains that while most cancers are sporadic, genomic testing can be used to identify hereditary cancer risk factors based on family history, pathology, and personal history. It also outlines how genomic analysis of tumor cells can provide information for prognosis, targeted therapy, and screening. The future of cancer care will likely involve more widespread, cheaper, and faster genomic testing to enable personalized treatment and pharmacogenomic testing.Basic principles of cancer therapy
Chemotherapy uses cytotoxic drugs to treat cancer by killing cancer cells. There are several types of chemotherapy treatments that are selected based on the type, stage, and genetics of the cancer. The goals of chemotherapy can be curative, aiming to eradicate the cancer through induction, consolidation, and maintenance therapy, or palliative to provide comfort and improve quality of life for advanced cancers. A case study is then presented to demonstrate chemotherapy treatment in practice.
Crpc the paradigm of sequence
Describing the importance and how to choose the first line in CRPC emphasising the role of chemotherapy.
NEOPLASIA: CARCINOGENESIS
Carcinogenesis is a multistep process involving genetic mutations that cause cells to proliferate uncontrollably. There are four classes of regulatory genes involved: 1) growth promoters like proto-oncogenes that become activated oncogenes, 2) inhibitors like tumor suppressor genes, 3) genes regulating apoptosis, and 4) DNA repair genes. Genetic damage occurs through environmental and spontaneous mutations and fails to be repaired if the DNA damage response is defective. This can result in oncogene activation and tumor suppressor inactivation, leading to autonomous growth, evasion of growth inhibition, apoptosis resistance, limitless replication through telomerase expression, angiogenesis, invasion and metastasis. Cancer progression involves the accumulation of additional mutations that
Cancer biology
Cancer biochemistry involves biochemical alterations in cancer cells. Specific objectives include listing protooncogenes and tumor suppressor genes, and explaining their roles and mechanisms of action. Protooncogenes become oncogenes through activation mechanisms like mutations. Tumor suppressor genes like p53 regulate cell proliferation and their mutation leads to cancer. Cyclins and cell cycle phases are also discussed. Standard cancer treatments include surgery, radiotherapy, and chemotherapy using antimetabolite drugs. Tumor markers can be used for cancer diagnosis, prognosis, localization, and treatment monitoring and are classified based on their type.
General principles in chemotherapy of cancer
This document provides an overview of general principles in cancer chemotherapy. It discusses that chemotherapy uses cytotoxic drugs to destroy malignant cells. Drugs can be cell cycle specific, killing dividing cells, or nonspecific, killing resting and dividing cells. Combination chemotherapy using multiple drugs with different mechanisms of action is now common to achieve total tumor cell kill. Careful scheduling of cell cycle specific and nonspecific drugs is important. Tumors can become resistant to repeated use of single drugs through selection of less responsive cells or mutations altering drug targets. The goal of chemotherapy is complete remission through use of maximum tolerated drug doses in combination regimens.
IHC in breast CA
1) Breast cancer subtypes are classified based on receptor expression as luminal, basal, or HER2-enriched and these subtypes determine treatment options and prognosis.
2) IHC testing plays an important role in classifying subtypes but results can be affected by testing methods. ER, HER2, and Ki67 are key markers but cut-offs and interpretation require care.
3) The 21-gene Oncotype DX assay provides a recurrence score that predicts chemotherapy benefit in node-negative breast cancer, guiding treatment decisions according to risk categories defined in clinical trials.
Leptomeningeal mets in solid tumors
This document discusses leptomeningeal metastasis (LM), including:
- LM occurs in 5% of cancer patients symptomatically and 20% asymptomatically, most commonly from breast, lung, melanoma, and gastrointestinal cancers.
- Symptoms include headache, vomiting, altered mental status, cranial nerve palsies, and neck stiffness in rare cases.
- MRI of the entire neuraxis is the most sensitive imaging method. CSF analysis has a sensitivity of 45-55% initially, increasing to 80% with a second lumbar puncture.
- Treatment options discussed include surgery, radiation therapy targeted to involved sites, whole brain radiation, and intraventricular chemotherapy via Ommaya reservoir. Median survival is
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Fight Colorectal Cancer
This document summarizes key findings from the PRIME trial evaluating the addition of panitumumab to FOLFOX4 as first-line treatment for metastatic colorectal cancer. Biomarker analysis found that KRAS exon 2 wild-type tumors derived greater benefit from the addition of panitumumab, with a progression-free survival advantage compared to FOLFOX4 alone. Further biomarker testing found mutations in other RAS isoforms or BRAF reduced likelihood of benefit from panitumumab. The results support use of RAS/BRAF mutation testing to select patients for first-line anti-EGFR therapy in combination with chemotherapy.Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...
Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...Prof. Eric Raymond Oncologie Medicale
This oral presentation made during ESMO 2016 highlight novel targets and drugs developed for patients with advanced neuroendocrine tumors. This includes targeted agents aiming probing cell signaling in tumor microenvironment and immune responses. Genetic alterations on major anti-oncogenes are reported in the perspective of pathway activations. Combinations using VEGFR, mTOR, Somatostatin receptors inhibitors with novel strategies and immunotherapy are also suggested. This presentation focuses mainly on gastrointestinal neuroendocrine tumors but may also be of interest for those involved in the care of patients with thoracic neuroendocrine tumors.Chapter 5 hereditary cancer syndrome next generation
This document provides an overview of hereditary cancers and genetic testing. It discusses:
- The difference between sporadic and hereditary cancers, with hereditary cancers making up 10% of cases and being caused by germline mutations passed down from a parent.
- Several hereditary cancer syndromes are described in detail, including BRCA1/2 associated with breast and ovarian cancer, Li-Fraumeni syndrome, Cowden syndrome, and Lynch syndrome.
- Surveillance recommendations are provided for each syndrome to enable early cancer detection.
- The role of genetic testing is discussed to identify mutations that cause hereditary cancer syndromes and guide patient management.
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
This randomized clinical trial compared autologous stem cell transplantation (ASCT) versus continued therapy without transplantation in newly diagnosed multiple myeloma patients. 389 patients received induction with lenalidomide-dexamethasone (Rd) or cyclophosphamide-lenalidomide-dexamethasone (CRD). Patients were then randomized to receive ASCT or continued Rd or CRD therapy. The primary endpoint was progression-free survival (PFS). Results showed ASCT improved PFS compared to continued therapy without transplantation. However, overall survival was not significantly different between the two groups, suggesting continued therapy without ASCT may be sufficient for some patients.
Indolent Non-Hodgkin’s Lymphoma Sharman slides
This document discusses indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It provides information on treatment options and clinical trials for these conditions. The document lists faculty members and their disclosures. It then provides data from clinical trials comparing rituximab maintenance therapy to watchful waiting in asymptomatic follicular lymphoma, and comparing rituximab maintenance to retreatment in low tumor burden follicular lymphoma. Outcomes for different chemotherapy regimens in lymphoma are also presented.
Genomics and Cancer
The study of cancer genomes has revealed abnormalities in genes that drive the development and growth of many types of cancer. This knowledge has improved our understanding of the biology of cancer and led to new methods of diagnosing and treating the disease.
A 2020 Renal Cancer update
An update of the pathophysiology of renal cell cancer including the latest therapeutic pathways and management
Chapter 38 role of surgery in cancer prevention
The document discusses the role of surgery in preventing cancers caused by hereditary genetic mutations. It focuses on several high-risk cancer syndromes including BRCA1/2 mutations which increase breast and ovarian cancer risk, CDH1 mutations which increase stomach cancer risk, and APC mutations which cause Familial Adenomatous Polyposis (FAP) and increase colon cancer risk. For each, it describes the associated cancer risks, genetic testing recommendations, surveillance guidelines, and risk-reducing surgical options such as prophylactic mastectomies, salpingo-oophorectomies, and gastrectomies. The timing of such surgeries is based on the earliest age of cancer onset in the
What's hot (20)
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...
Precision Medicine in Neuroendocrine Tumors: Targeted Drugs, Where Are We Hea...
Chapter 5 hereditary cancer syndrome next generation
Chapter 5 hereditary cancer syndrome next generation
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
Ohio State's 2016 ASH Review - BEST OF ASH 2015 MULTIPLE MYELOMA AND PLASMA C...
Viewers also liked
Aung citt nyein
This study evaluated the efficacy and toxicity of a complex combination biochemotherapy regimen for 25 patients with advanced metastatic melanoma. A complete response was seen in 2 patients, partial response in 2 patients, and stable disease in 9 patients. The most common toxicities were lethargy, fever, nausea, vomiting, thrombocytopenia, leukopenia, and neutropenia. Doses of vindesine, cisplatin, and IL-2 often had to be reduced due to toxicities. The regimen showed an objective response rate of 16% with an 8% complete response rate, but dose reductions were frequently required due to treatment-related side effects.
Sithu ko
The document analyzes the frequency and types of congenital heart diseases in newborns admitted to Tuschinskaya Children's Hospital from 2000 to 2009. It found that septal defects were the most common at 95.6% of cases, with atrial septal defects being the most frequent at 80.5%. The median frequency of congenital heart diseases in newborns each year was 4%. Patients were treated medically to address symptoms until they could undergo surgical treatment. A case study of a newborn with atrioventricular septal defect and patent ductus arteriosus requiring intensive care treatment is also described.
Zaw htet
1) This study analyzed prognostic factors that influence survival in patients with relapsed follicular lymphoma by examining clinical data from 151 patients.
2) Univariate analysis found that factors like older age, poorer performance status, advanced stage, short duration of response to initial therapy, and not achieving complete response were associated with worse survival.
3) Multivariate analysis identified that duration of response to initial therapy and performance status at relapse were the most important predictors of long-term survival, with patients having responses lasting 2+ years or good performance status having longer 5-year survival.
Personas with Personality
Creating personas can be a great way to segment your customer base into marketable audiences. Follow along as we lay out how to create a killer customer persona.
PPC Attribution: A Portent & Hanapin Webinar
Michael Wiegand and Cassie Oumedian walk through choosing an attribution model for your business that'll give you greater insight into paid campaign performance. Last click attribution is dead. Bury it and move on to another model!
Aung thiha soe
Lung cancer is a leading cause of cancer deaths worldwide. This retrospective study analyzed 95 patients with stage III-IV non-small cell lung cancer treated with first-line combination chemotherapy and second-line single-agent chemotherapy. The study found that the gemcitabine, platinum-based chemotherapy, and radiotherapy (GPR) regimen had a higher clinical response rate (21.3%) compared to other regimens. Leucopenia and fatigue were common toxicities for first-line treatment, while diarrhea was common for second-line treatment. The study concluded that while no regimen was statistically significantly better, GPR appeared to be more effective with acceptable toxicity.
Tanl power point
The study aimed to examine respiratory diseases in newborns, especially respiratory distress syndrome (RDS), and the relationship between gestational age, birth weight and RDS. It analyzed 30 newborns admitted to the neonatal intensive care unit and neonatal department from January to February 2008. The findings were that RDS predominantly affects preterm infants under 32 weeks gestation. Treatment for RDS included surfactant therapy, CPAP, ventilation and antibiotics. Combinations and durations of antibiotics depended on the diagnosis and severity of the condition.
Viewers also liked (7)
Similar to Kyaw thura zaw
Newly Diagnosed Myeloma
The document summarizes the best approaches to treating newly diagnosed multiple myeloma based on patient fitness level and risk profile. For fit patients, phase 3 trials show superior outcomes with bortezomib-containing triple-drug induction regimens followed by stem cell collection and autologous stem cell transplant compared to doublet regimens. For unfit patients, bortezomib-melphalan-prednisone or lenalidomide-low dose dexamethasone are standard first-line options. High-risk patients with genomic abnormalities may benefit from enrollment in clinical trials or bortezomib-containing consolidation/maintenance therapies with consideration of autologous stem cell transplant.
Metastatic renal cell carcinoma
Metastatic renal cell carcinoma (mRCC) has generally poor outcomes with median survival of less than one year. Surgery and chemotherapy are often not effective, leaving patients underserved. The introduction of molecularly targeted therapies like sorafenib and sunitinib have improved outcomes. Cytoreductive nephrectomy followed by targeted therapy may provide benefits for select patients based on prognostic models. Immunotherapy agents are also options for treating mRCC by releasing brakes on the immune system. Ongoing research continues to evaluate combination therapies and predictive biomarkers.
Renal Cell Carcinoma Diagnosis And Management
This document provides an overview of renal cell carcinoma (RCC), including its epidemiology, pathology, clinical presentation, evaluation and staging, prognosis, and treatment options. RCC incidence has been rising and is more common in men than women. Surgery is the main treatment for localized RCC, while targeted therapies like sorafenib and sunitinib have improved outcomes for metastatic RCC compared to previous chemotherapy options. Ongoing clinical trials are exploring adjuvant and neoadjuvant therapies to improve prognosis.
Vorinostat Case Study
Vorinostat, a small molecule HDAC inhibitor, was studied in small phase I and II trials for refractory differentiated thyroid cancers, but results were clinically disappointing. The response rate was 0% and only 56% of patients experienced stable disease for 6 months. Its effect on radioiodine uptake was not tested. Other drugs studied for refractory thyroid cancers include rosiglitazone, lithium carbonate, thalidomide, bortezomib, and combretastatin A4 phosphate, but significant clinical benefit was not observed.
Immunotherapies in management of HCC
This document discusses immunotherapies for hepatocellular carcinoma (HCC). It begins by explaining that HCC typically develops in the context of chronic liver disease and cirrhosis. For early-stage HCC, surgical resection and liver transplantation can be curative, while radiofrequency ablation and transarterial chemoembolization are common local therapies for intermediate-stage HCC. Systemic therapies were historically ineffective for advanced HCC, but tyrosine kinase inhibitors like sorafenib were found to provide a survival benefit. More recent immunotherapies like nivolumab, pembrolizumab, and combinations with ipilimumab have shown response rates of 15-31% in advanced HCC
METASTATC COLORECTAL CANCER IN 2017
This document summarizes a presentation on the management of metastatic colorectal cancer (mCRC) in 2017. It discusses several key points:
1) Patient stratification is important in determining treatment approach for mCRC, taking into account factors like disease extent and symptoms.
2) A multidisciplinary team approach is mandatory for developing optimal treatment plans.
3) Assessment of predictive biomarkers like RAS mutations helps determine which first-line treatments may be most effective.
4) Tumor location (right vs left-sided colon cancer) can impact treatment outcomes and response to certain drugs like anti-EGFR therapies.
5) Multiple clinical trials over time have led to improved survival outcomes and more
Hepatoblastoma- Investigations and management
This document summarizes information about hepatoblastoma, a rare type of liver cancer that mostly affects young children. It discusses the history and terminology of hepatoblastoma. Key points include: hepatoblastoma typically affects children under 3 years old and accounts for about 1% of childhood cancers. Complete surgical resection is the main treatment when possible but less than 50% of patients are resectable at diagnosis. The addition of cisplatin-based chemotherapy has improved outcomes by increasing resectability. Prognosis remains suboptimal for patients with unresectable or metastatic disease after chemotherapy. Chemoembolization and liver transplantation are promising alternative treatments in these cases.
apmlseminarmine
Jubair, a 12-year-old boy, was admitted with fever, pallor, blackish spots on his body, gum bleeding, and blood in his stool. Tests found low blood cell counts, elevated D-dimer and fibrinogen levels, and 60% promyelocytes in his bone marrow. Immunophenotyping and a genetic test confirmed the diagnosis of acute promyelocytic leukemia (APL). APL is a subtype of acute myeloid leukemia characterized by a genetic mutation and sensitivity to all-trans retinoic acid treatment. Without prompt treatment, APL patients are at high risk of life-threatening bleeding. Jubair received supportive care and induction chemotherapy including all-trans retino
BP JCSO RCC Supplement_FINAL
This document summarizes a study evaluating the efficacy and safety of nivolumab compared to everolimus for treating advanced renal cell carcinoma (RCC) that has progressed after anti-angiogenic therapy (Checkmate 025). The study found that nivolumab provided a statistically significant improvement in overall survival compared to everolimus, with median survival of 25 months for nivolumab vs 19.6 months for everolimus. Nivolumab also had higher response and duration of response rates. While grade 3-4 adverse events were more common with nivolumab, fewer patients discontinued due to adverse reactions compared to everolimus. The study demonstrates the benefit of nivolumab immunotherapy for previously treated
Erbitux
This case study examines the use of cetuximab-based chemotherapy for the re-treatment of patients with metastatic colorectal cancer who had previously responded to cetuximab treatment but experienced disease progression after stopping treatment. The study aims to evaluate the overall response and safety of re-treating these patients with cetuximab-containing chemotherapy. It describes the study design, inclusion/exclusion criteria, experimental and control treatments, and primary/secondary outcome measures that will be assessed over a 2-year period.
Cancer chemotherapy part I
This document discusses pharmacology of antineoplastic agents. It begins by classifying antineoplastic agents into cell cycle specific agents, cell cycle non-specific agents, and miscellaneous agents like antibodies. It then discusses mechanisms of action, side effects, and drug resistance. Specific agents and their mechanisms, uses, and side effects are outlined. Alkylating agents like cyclophosphamide and mechanisms like crosslinking DNA are explained in detail.
Cancer chemotherapy part i
This document discusses pharmacology of antineoplastic agents. It begins by classifying antineoplastic agents into cell cycle specific agents, cell cycle non-specific agents, and miscellaneous agents like antibodies. It then discusses mechanisms of action, side effects, and drug resistance. Specific agents and their mechanisms, uses, and side effects are outlined. Alkylating agents like cyclophosphamide and mechanisms like crosslinking DNA are explained in detail.
Cholangiocarcinoma
This document provides an overview of cholangiocarcinoma, a rare and deadly form of cancer. It discusses risk factors and increasing incidence rates. For localized disease, surgical resection is standard but outcomes remain poor. For advanced disease, gemcitabine-based chemotherapy is the standard first-line treatment based on results from the ABC-02 trial showing improved survival with gemcitabine and cisplatin. Retrospective data on second-line therapies and combination of pazopanib and trametinib show some benefit. Adding radiation therapy may also improve outcomes based on another retrospective review. Next generation sequencing is helping identify molecular alterations to guide targeted therapy trials. Ongoing clinical trials at MD Anderson include testing new
Prostate cancer
Academic Discussion on the management of Prostate cancer by Dr. Abhishek Basu (MD, DNB) for Radiation oncology & Medical oncology residents.
Advances in Melanoma Oncology - Mike Atkins, MD
Advances in immunotherapy, including checkpoint inhibitors targeting CTLA-4 and PD-1, have significantly improved outcomes for patients with metastatic melanoma. Combination immunotherapy with nivolumab and ipilimumab produces response rates over 60%, compared to around 40% for nivolumab alone and 11% for ipilimumab alone. Many patients receiving the combination immunotherapy continue to respond even after stopping treatment, achieving a state of treatment-free survival. While combination immunotherapy is more toxic than single-agent treatments, the toxicities are often manageable. Ongoing research continues to explore optimizing combination immunotherapy regimens to improve outcomes while reducing toxicity.
Immunotherapy and Heme/Onc Emergencies for Emergency Medicine
A primer on Immunotherapy, SVC Syndrome, and Blast Crisis for Emergency Medicine resident physicians. Delivered May 15, 2019. #EMconf
Slide deck updates on cml (1)
Dasatinib is an effective first-line treatment for chronic myeloid leukemia (CML) based on results from the DASISION trial. The trial showed that dasatinib induced higher and faster rates of complete cytogenetic response and major molecular response compared to imatinib. At 5 years of follow-up, dasatinib maintained superior rates of molecular responses including deeper responses below 0.1% BCR-ABL1. Dasatinib therefore provides improved long-term outcomes for patients with newly diagnosed CML compared to standard imatinib treatment.
Chemotherapy in rhabdomyosarcoma
This illustrates the role of chemotherapy in rhabdomyosarcoma along with brief description of pathology, staging etc.
Tumour marker
Tumor markers are biological substances released by tumor cells or the body in response to tumors that can be detected at higher-than-normal levels in bodily fluids. They provide information about cancer screening, diagnosis, staging, prognosis, therapy, and monitoring. No single tumor marker is perfect, but some common and useful ones include CEA for colorectal cancer, AFP for liver and testicular cancers, CA19-9 for pancreatic cancer, PSA for prostate cancer, and CA125 for ovarian cancer. Newer markers based on DNA, RNA, and proteins are continually being discovered and evaluated to improve cancer detection and management.
Acute Promyelocytic Leukaemia
Jubair, a 12-year-old boy, was admitted with fever, pallor, blackish spots on the body, gum bleeding, and blood in stool. Examination found pallor, gum swelling, and enlarged liver and spleen. Tests showed low blood cell counts, elevated D-dimer and fibrinogen levels. Bone marrow biopsy found 60% promyelocytes. Immunophenotyping and genetic testing confirmed the diagnosis of acute promyelocytic leukemia (APL). APL is a type of acute myeloid leukemia characterized by a genetic mutation and abnormal promyelocytes. It requires emergent treatment including all-trans retinoic acid (ATRA) to induce differentiation and prevent potentially fatal
Similar to Kyaw thura zaw (20)
Immunotherapy and Heme/Onc Emergencies for Emergency Medicine
Immunotherapy and Heme/Onc Emergencies for Emergency Medicine
More from zawhtet1984
Yehlaingbwar
This document discusses prognostic factors in epithelial ovarian cancer. It analyzes data from 55 patients treated with primary surgery and chemotherapy between 2005-2009. The key findings are:
1. Significant prognostic factors in univariate analysis included age, histology, FIGO stage, and ascites.
2. Patients aged 70 or older and with FIGO stage IV cancer had poorer prognoses, with a 31-month survival time. Patients with endometrioid or clear cell histology had longer survival, at 51 months.
3. Subgroups like endometrioid/clear cell histology, FIGO stage II, and those with ascites were also significant prognostic factors in univariate analysis.
Pyae phyo aung's thesis (breast cancer)
This study examined the significance of HER-2 and hormonal receptor status in patients with locally advanced breast cancer treated with neoadjuvant systemic therapy. It found that hormonal receptor status has a significant prognostic effect on both overall survival and progression-free survival. HER-2 receptor status was found to have a significant prognostic effect on overall survival. No significant association was found between receptor status and clinical response to neoadjuvant chemotherapy. The study was limited by its small sample size and retrospective design.
Powerpoint presentation by dr sathiha
This study compared the effectiveness of two chemotherapy regimens, BEACOPP and COPP-ABVD, for treating advanced Hodgkin's lymphoma. 49 patients received either BEACOPP (25 patients) or COPP-ABVD (24 patients). The rate of freedom from treatment failure at 5 years was higher for BEACOPP at 76% compared to 69% for COPP-ABVD. Overall survival rates at 5 years were also higher for BEACOPP at 88% versus 83% for COPP-ABVD. While BEACOPP resulted in better tumor control and survival, it also had more acute toxicity including grade 4 leukopenia in some cycles.
Khant zaw aung
This study compared the efficacy and toxicities of gemcitabine/cisplatin combination chemotherapy and paclitexal/carboplatin combination chemotherapy as first-line treatment for 53 patients with stage IIIB or IV non-small cell lung cancer. The study found that gemcitabine/cisplatin combination resulted in better response rates but not statistically significantly so. It also found that gemcitabine/cisplatin combination resulted in more hematological toxicities. Patient demographics were not significantly different between the two treatment arms. The study concluded that platinum-based combinations are effective for non-small cell lung cancer but require proper premedications.
Chan myae htut
The document presents findings from a study comparing CHOP chemotherapy alone versus CHOP plus rituximab in elderly patients with diffuse large B cell lymphoma. The study found that adding rituximab to CHOP chemotherapy significantly increased complete response rates, decreased treatment failure and relapse rates, and improved event-free and overall survival compared to CHOP alone, without significantly increasing toxicity.
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
The document discusses nutrition for preterm and congenitally small infants. It notes that preterm infants have high nutritional needs for optimal growth. Early minimal enteral feeding can provide advantages like faster weight gain and shorter hospital stays compared to parenteral nutrition alone. Breast milk is preferable to preterm formula due to beneficial components, though formula provides more calories, proteins and minerals. The study assessed the effectiveness of different nutrition methods in 30 preterm and small infants, finding that a combination of preterm formula and breast milk was most effective for growth.
More from zawhtet1984 (6)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Recently uploaded
How to Add Chatter in the odoo 17 ERP Module
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar KanvariaNatural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityAkanksha trivedi rama nursing college kanpur.
Natural birth techniques are various type such as/ water birth , alexender method, hypnosis, bradley method, lamaze method etcPengantar Penggunaan Flutter - Dart programming language1.pptx
Pengantar Penggunaan Flutter - Dart programming language1.pptx
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
clinical examination of hip joint (1).pdf
described clinical examination all orthopeadic conditions .
Hindi varnamala | hindi alphabet PPT.pdf
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)Academy of Science of South Africa
A workshop hosted by the South African Journal of Science aimed at postgraduate students and early career researchers with little or no experience in writing and publishing journal articles.LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
This Dissertation explores the particular circumstances of Mirzapur, a region located in the
core of India. Mirzapur, with its varied terrains and abundant biodiversity, offers an optimal
environment for investigating the changes in vegetation cover dynamics. Our study utilizes
advanced technologies such as GIS (Geographic Information Systems) and Remote sensing to
analyze the transformations that have taken place over the course of a decade.
The complex relationship between human activities and the environment has been the focus
of extensive research and worry. As the global community grapples with swift urbanization,
population expansion, and economic progress, the effects on natural ecosystems are becoming
more evident. A crucial element of this impact is the alteration of vegetation cover, which plays a
significant role in maintaining the ecological equilibrium of our planet.Land serves as the foundation for all human activities and provides the necessary materials for
these activities. As the most crucial natural resource, its utilization by humans results in different
'Land uses,' which are determined by both human activities and the physical characteristics of the
land.
The utilization of land is impacted by human needs and environmental factors. In countries
like India, rapid population growth and the emphasis on extensive resource exploitation can lead
to significant land degradation, adversely affecting the region's land cover.
Therefore, human intervention has significantly influenced land use patterns over many
centuries, evolving its structure over time and space. In the present era, these changes have
accelerated due to factors such as agriculture and urbanization. Information regarding land use and
cover is essential for various planning and management tasks related to the Earth's surface,
providing crucial environmental data for scientific, resource management, policy purposes, and
diverse human activities.
Accurate understanding of land use and cover is imperative for the development planning
of any area. Consequently, a wide range of professionals, including earth system scientists, land
and water managers, and urban planners, are interested in obtaining data on land use and cover
changes, conversion trends, and other related patterns. The spatial dimensions of land use and
cover support policymakers and scientists in making well-informed decisions, as alterations in
these patterns indicate shifts in economic and social conditions. Monitoring such changes with the
help of Advanced technologies like Remote Sensing and Geographic Information Systems is
crucial for coordinated efforts across different administrative levels. Advanced technologies like
Remote Sensing and Geographic Information Systems
9
Changes in vegetation cover refer to variations in the distribution, composition, and overall
structure of plant communities across different temporal and spatial scales. These changes can
occur natural.
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxMohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
The Diamonds of 2023-2024 in the IGRA collection
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Aberdeen
How to Make a Field Mandatory in Odoo 17
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective UpskillingExcellence Foundation for South Sudan
Strategies for Effective Upskilling is a presentation by Chinwendu Peace in a Your Skill Boost Masterclass organisation by the Excellence Foundation for South Sudan on 08th and 09th June 2024 from 1 PM to 3 PM on each day.Recently uploaded (20)
Liberal Approach to the Study of Indian Politics.pdf
Liberal Approach to the Study of Indian Politics.pdf
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Pengantar Penggunaan Flutter - Dart programming language1.pptx
Pengantar Penggunaan Flutter - Dart programming language1.pptx
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Kyaw thura zaw
- 1. M.V. LOMONOSOV MOSCOW STATE UNIVERSITY FACULTY OF BASIC MEDICINE COMPARISON OF POLY- CHEMOTHERAPY (CVD regimen) & THE SAME CHEMOTHERAPY (CT) PLUS INTERFERON-α2a IN METASTATIC MELANOMA Student: Dr. Kyaw Thura Zaw Scientific Supervisor : Prof. Dr. Lev Demidov N.N. BLOKHIN CANCER RESEARCH CENTRE Moscow ,2010
- 5. Race Melanoma is more common in whites than in blacks and Asians. The rate of melanoma in blacks is estimated to be 1/120 that of whites. Sex Melanoma is slightly more common in men than women (1.2:1). Melanoma is the 5th most common malignancy in men and the 6th most common malignancy in women, accounting for 5% and 4% of all new cancer case. respectively.
- 7. A=Asymmetry B=Border (irregular) C= Color D= Diameter ABCD Properties of Radial Melanomas
- 8. A 1.5-cm melanoma with characteristic asymmetry, irregular borders, and color variation.
- 10. AIM OF STUDY To Study and Compare the Poly-chemotherapy (CVD regimen) & the Same Chemotherapy(CT)plus Interferon α - 2 a in Metastatic Melanoma.
- 13. Patient’s Characteristics CVD P CVD+IFN P Age , median (min-max) 55 (35-65) P<0.01 52(30-65) P<0.10 ECOG PS 0 2 P=1.00 2 P=1.00 1 3 P>0.10 6 P>0.25 2 10 P>0.10 7 P>0.30 Metastatic sites Skin 4 P>0.25 6 P>0.10 Lymph node 10 P>0.70 9 P>0.25 Lungs 9 P=1.00 9 P=1.00 Liver 9 P>0.10 6 P>0.10 Other 3 P>0.10 0 P>0.20 Number of Metastases 1 1 P>0.10 4 P>0.10 2 8 P>0.70 7 P>0.70 3 6 P>0.25 4 P>0.25
- 17. Overall survival. Heavy line represents CVD + IFN group; Fine line represents CVD group ; No. of death /Total No. Average survival Survival Median CVD+IFN 8/15 13.51(9.7;17.3) 12.0(9.9;14.1) CVD 7/15 10.75(9.1;12.4) 12.0(7.8;16.2)